Manlulu Anthony, Lee Tak Wai, Wan Innes, Law Chun Yat, Chang Carlin, Garzon Juan Carlos, Yim Anthony
Division of Cardiothoracic Surgery, the Chinese University of Hong Kong, SAR, China.
Chest. 2005 Nov;128(5):3454-60. doi: 10.1378/chest.128.5.3454.
Minimal-access thymectomy has become increasingly popular as surgical treatment for patients with nonthymomatous myasthenia gravis (NTMG) because of its comparable efficacy, safety, and lesser degree of tissue trauma compared with conventional open surgery. We reviewed and analyzed our data on video-assisted thoracic surgery (VATS) thymectomy and present the clinical outcomes according to the Myasthenia Gravis Foundation of America classification.
A retrospective review of VATS thymectomy for NTMG in a university hospital over a 12-year period. Data were collected from the medical records and supplemented with telephone surveys. The impact of surgery and other variables potentially affecting complete stable remission (CSR) were calculated using Kaplan-Meier survival curves; comparisons between survival curves was performed using the log-rank test.
A total of 38 consecutive patients underwent VATS thymectomy for NTMG. Median postoperative stay was 3 days. Pathologic examination revealed thymic hyperplasia in 61.1% of cases, normal thymus in 22.2%, and thymic atrophy in 16.6%. There was no perioperative mortality; complications occurred in four patients. After a median follow-up of 69 months, 91.6% of patients experienced improvement, with crude CSR achieved in 22.2%. Kaplan-Meier survival curve demonstrated a 75% CSR rate at 10-year follow-up. On univariate analysis, only disease duration < or = 12 months (p = 0.03) was associated with a statistically significant improvement in CSR.
VATS thymectomy for NTMG results in symptomatic improvement in the vast majority of patients, with a high rate of CSR. The procedure is associated with low morbidity and no perioperative mortality. Future studies on thymectomy for myasthenia gravis should be reported in a standardized manner to allow accurate comparisons between results in the absence of randomized prospective trials.
由于与传统开放手术相比,疗效相当、安全性高且组织创伤程度较小,微创胸腺切除术已越来越多地用于非胸腺瘤型重症肌无力(NTMG)患者的外科治疗。我们回顾并分析了我们关于电视辅助胸腔镜手术(VATS)胸腺切除术的数据,并根据美国重症肌无力基金会的分类展示了临床结果。
对一所大学医院12年间NTMG患者接受VATS胸腺切除术进行回顾性研究。数据从病历中收集,并通过电话调查进行补充。使用Kaplan-Meier生存曲线计算手术及其他可能影响完全稳定缓解(CSR)的变量的影响;使用对数秩检验对生存曲线进行比较。
共有38例连续患者接受了NTMG的VATS胸腺切除术。术后中位住院时间为3天。病理检查显示61.1%的病例为胸腺增生,22.2%为正常胸腺,16.6%为胸腺萎缩。无围手术期死亡;4例患者出现并发症。中位随访69个月后,91.6%的患者病情改善,22.2%达到粗略的CSR。Kaplan-Meier生存曲线显示10年随访时CSR率为75%。单因素分析显示,只有病程≤12个月(p = 0.03)与CSR的统计学显著改善相关。
NTMG患者接受VATS胸腺切除术可使绝大多数患者症状改善,CSR率高。该手术并发症发生率低,无围手术期死亡。未来关于重症肌无力胸腺切除术的研究应以标准化方式报告,以便在缺乏随机前瞻性试验的情况下准确比较结果。